Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

Study Showed Larazotide Acetate Prevented Immunologic Changes Induced by

Gluten in Patients with Celiac Disease Additional Data Indicates Potential in Treating Inflammatory Bowel Disease

ORLANDO, Fla., Oct. 7 /PRNewswire/ -- Alba Therapeutics Corporation presented results from two clinical studies this week at the American College of Gastroenterology (ACG) 2008 Annual Scientific Meeting. Data from study CLIN 1001-004, the first Phase IIa trial conducted in celiac disease and the first to assess the prevention of immunologic changes in celiac disease, showed that larazotide acetate (AT-1001) successfully demonstrated prevention of gluten-induced immunologic changes in celiac patients.

Results from the study showed that larazotide acetate is the first pharmacologic agent to prevent changes in blood mononuclear cell populations (specifically T-reg cells and B Cells) and other markers of immunological change associated with active celiac disease. This data suggests that larazotide acetate offers potential as a future treatment of celiac disease. Results from a second poster presented at ACG showed that larazotide acetate also inhibited the effect of inflammatory cytokines, including tumor necrosis factor (TNF-alpha) and interleukin (IL-4) on intestinal epithelial permeability, in vitro, further suggesting that the product offers potential as a future treatment for inflammatory bowel disease (IBD).

Larazotide Acetate is a novel, non-absorbed peptide currently being studied in Phase IIb trials for the treatment of celiac disease. Larazotide acetate has the potential to become the first approved medicine to treat celiac disease and has been granted "Fast Track" designation from the U.S. Food and Drug Administration (FDA) for this indication.

Celiac disease affects approximately one percent of individuals in the United States and Europe, or approximately 6.5 million individuals. The only accepted management for the dise
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
(Date:4/23/2014)... in the popular Swedish children,s TV show Bolibompa, ... A new study from the University of Gothenburg ... programmes as well as the link between young ... , Steingerdur Olafsdottir,s doctoral thesis focuses on the ... TV show Bolibompa. Healthy foods dominated in the ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/22/2014)... popular high school sport in the United States with ... researchers in the Center for Injury Research and Policy ... and describe the occurrence and distribution patterns of basketball-related ... athletic training setting among adolescents and teens. , The ... Training , examined data relating to adolescents 13-19 years ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
Breaking Medicine News(10 mins):Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... BlueCross BlueShield of South Carolina announced today that the ... held during lunchtime hours on Wednesday, April 29, 2009.Blue ... well as other employers, will encourage their employees to ... in a 30-minute lunchtime walk. The goal of National ...
... 2 Accelerated Community Oncology Research Network (ACORN(TM)), ... highlights of its annual Principal Investigators, Meeting held ... from community-based oncology practices throughout the United States ... emerging treatment trends, as well as promising new ...
... to Include 24-oz and Convenient 4-oz Travel Size ... (Nasdaq: PURE ) today announced an ... PURE,s silver dihydrogen citrate (SDC)-based disinfectant as OneShot ... OneShot Plus product line. OneShot Plus DD ...
... BIGLERVILLE, Pa., March 2 The first Eklin ... recently installed at Dr.,Flake,s Animal Wellness Clinic which ... Oxford. The state-of-the-art system,from Eklin Medical Systems, the ... benefit the area,s thousands of veterinary patients,supporting the ...
... SynCare, LLC, announces the extension of its contract ... management. MHS, a Medicaid Managed Care Company, serving SCHIP ... assist the company in providing comprehensive care and support ... to continuing our partnership with SynCare for prenatal care ...
... are vegans and vegetarians most affected, study says , , MONDAY, March ... B12 in their blood before and after conception have a greater ... a new study says. , Most at risk may ... meat and animal-based foods, noted an American and Irish research team ...
Cached Medicine News:Health News:S.C. BlueCross to Celebrate Third Annual National Walk @ Lunch Day With Community Events in Columbia, Charleston, Greenville 2Health News:ACORN's Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting 2Health News:ACORN's Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 2Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 4Health News:Dr. Flake's Animal Wellness Clinic Installs Adams County's First Eklin Digital Radiography System 2Health News:Dr. Flake's Animal Wellness Clinic Installs Adams County's First Eklin Digital Radiography System 3Health News:SynCare Receives Managed Health Services Contract Renewal 2Health News:B12 Deficit May Boost Risk of Birth Defects 2
... Control is a liquid control ... busy immunoassay laboratory. With a ... serum based control can replace ... products for immunoassay and therapeutic ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
Invacare 5 Oxygen Concentrator with Sens O2, 230 VAC - Intl....
The Acceava Trichomonas Rapid Test is an immunochromatographic assay that detects pathogen antigens directly from vaginal swabs. Results are rapid, occurring within approximately 10 minutes....
Medicine Products: